Drug Trial Radar · NCT06152042
Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
37
Actual
Start
Dec 28, 2023
Primary completion
May 20, 2025
Study completion Jul 18, 2025
Sponsor
- Lead sponsor
- Biomea Fusion Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 2 Trial of BMF-219 in Participants with Type 1 Diabetes Mellitus.
Conditions
- Type 1 Diabetes Mellitus
Interventions
BMF-219Drug
BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the effect on endogenous insulin secretionTime frame: 26 Weeks
Locations
11 sites in 2 countries. Site status is shown where the registry gives one.
Oceanic Research Group
North Miami Beach, Florida
Lucas Research, Inc.
Morehead City, North Carolina
Alliance for Multispecialty Research, LLC.
Norman, Oklahoma
University Diabetes & Endocrine Consultants
Chattanooga, Tennessee
Velocity Clinical Research
Dallas, Texas
Texas Diabetes & Endocrinology
Round Rock, Texas
Diabetes & Glandular Disease Clinic, P.A.
San Antonio, Texas
Consano Clinical Research, LLC
Shavano Park, Texas
Manassas Clinical Research Center
Manassas, Virginia
Dr. T.G Elliott Inc. dba BC Diabetes
Vancouver, British Columbia, Canada
Centricity Research
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.